Special Antibody Pipelines

• Morphosys and the HuCAL antibodies
• Morphotek and the Morphodoma antibodies
• Zenyth from Australia and antibodies
• Rinat Neuroscience and humanized antibodies
  

Special Company Pipeline

• NPS Pharmaceuticals
  

• Two clinical stage antibodies from HuCAL antibody technology;
• Anti-HLA-DR antibody in phase I for B-cell lymphoma at GPC Biotech;
• Anti-amyloid beta antibody ready for phase I at Roche;
• Abandoned anti-ICAM antibody projects;
• New in house priority for MOR103 against undisclosed target in rheumatoid arthritis;
• Anti-CD38 antibody under preclinical evaluation

Morphotek and the Morphodoma antibodies

• Fully human antibodies from high titer human hybridomas;
• Series of cell surface glycoporotein targets for use in oncology;
• Lead antibody MORAb-003 in phase I for ovarian cancer;
• IND for second antibody (MORAb-009) FDA-accepted for pancreatic cancer;
• Third antibody with potential IND in 2006;

Zenyth from Australia and antibodies

• Late stage development projects mostly licensed-in with territorial rights in Europe ;
• Biologics' projects include antibody, protein and peptide;
• In-house drug discovery for small molecules;
• Proprietary lead project cizorlitine in phase II/III for urinary stress incontinence;
• Indication focus in research on CNS targets

• Results of phase I/II evaluation of lead antibody RN624 against NGF in osteoarthritic pain soon to be presented;
• Antibody againsts the amyloid beta peptide scheduled for IND filing in Q1/2006;
• Further antibody and protein projects against undisclosed targets in preclinical R&D

NPS Pharmaceuticals

• Recombinant parathyroid hormone for osteoporosis close to approval in Europa and under BLA review in the US ;
• Analog of glucagon-like peptide 2 in phase III for short bowel syndrome;
• R&D collaboraton with GSK on calcium receptor antagonists (Calcilytics) for PTH release with phase I compounds;
• Ongoing drug discovery program with AstraZeneca targeting metabotropic glutamate receptors;